Nomura Holdings
PLX icon

Nomura Holdings’s Protalix BioTherapeutics PLX Stock Holding History

Nomura Holdings’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2,370
Closed -$109K – 2235
2013
Q3 		$109K Sell
2,370
-3,016
-56% -$155K ﹤0.01% 2057
2013
Q2 		$266K Buy
+5,386
New +$286K ﹤0.01% 1669

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Nomura Holdings's PLX Position: Q4 2013 in Review

Nomura Holdings sold out of Protalix BioTherapeutics (PLX) in Q4 2013, closing a stake of 2,370 shares — an estimated $109K sold.

Nomura Holdings first reported a position in PLX in Q2 2013 and held it in 2 quarters. The position peaked at $266K in Q2 2013. 45 funds tracked by Wall St. Rank hold PLX as of Q4 2013.

  • Nomura Holdings reported no remaining Protalix BioTherapeutics position as of Q4 2013 after selling out during the quarter.
  • Nomura Holdings sold 2,370 Protalix BioTherapeutics shares in Q4 2013, an estimated $109K.
  • Nomura Holdings first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 2 quarters.
  • Nomura Holdings's Protalix BioTherapeutics position peaked at $266K in Q2 2013.
  • 45 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2013.

Based on Nomura Holdings's 13F filing for Q4 2013, filed 14 Feb 2014.